Key result
New-onset device-detected atrial tachyarrhythmia in pacemaker or defibrillator patients significantly increased the risk of thromboembolic events (RR 2.88; 95% CI 1.79–4.64; P<0.001).
Why the study?
Does new-onset device-detected atrial tachyarrhythmia increase the risk of thromboembolic events in patients with pacemakers or defibrillators?
Meta-Analysis (n=24,984)
Does new-onset device-detected atrial tachyarrhythmia increase the risk of thromboembolic events in patients with pacemakers or defibrillators?
Effect estimate: RR 2.88 (95% CI 1.79-4.64)
p-value: p=<0.001
New-onset device-detected atrial tachyarrhythmia is common in patients with pacemakers or defibrillators and is associated with a nearly 3-fold increased risk of thromboembolic events.
No takes yet. Share an insight, caveat, or question.
Supports anticoagulation consideration in device patients with new-onset atrial tachyarrhythmia; confirms its association with thromboembolic risk.
Belkin et al. (2018) conducted a meta-analysis in Pacemaker or defibrillator patients (n=24,984). New-onset device-detected atrial tachyarrhythmia (DDAT) vs. No new-onset DDAT was evaluated on Thromboembolic events (TE) (RR 2.88, 95% CI 1.79-4.64, p=<0.001). New-onset device-detected atrial tachyarrhythmia in pacemaker or defibrillator patients significantly increased the risk of thromboembolic events (RR 2.88; 95% CI 1.79–4.64; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: